High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy

High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy

Abstract Background High tumour ribosomal RNA degradation (RNA disruption) during neoadjuvant chemotherapy has been associated with a post-treatment pathologic complete response (pCR) and improved disease-free survival (DFS) in breast cancer patients. We further assessed the relationship between tum...

Full description

Saved in:
Bibliographic Details
Main Authors: Amadeo M. Parissenti, Laura B. Pritzker, Maria Aanesland Dahle, Hedda von der Lippe Gythfeldt, Twinkle Masilamani, Gabriel Theriault, Renée St-Onge, Lavina D’costa, Ole Christian Lingjaerde, Mads Haugland Haugen, Olav Engebraaten
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Breast Cancer Research
Subjects:
Predictive biomarker
Tumour RNA disruption
HER2- breast cancer
NeoAva clinical trial
FEC-T
Bevacizumab
Online Access:https://doi.org/10.1186/s13058-025-02092-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13058-025-02092-9

Similar Items